Search results for "PROGNOSIS"

showing 10 items of 2052 documents

PBRM1 loss is a late event during the development of cholangiocarcinoma

2017

Aims: Somatic mutations in genes encoding chromatin remodellers have been reported recently in several cancer types, including approximately half of cholangiocarcinomas. One of the most commonly mutated chromatin remodellers in cholangiocarcinoma is the Polybromo-1 (PBRM1) gene located on chromosome 3p21, which encodes a subunit of the SWI/SNF complex. The aim of this study was to determine the timing of PBRM1 mutations in biliary carcinogenesis. Methods and results: In order to accomplish this goal, we used immunohistochemistry to assess PBRM1 protein expression in a series of precursor lesions and invasive biliary carcinomas. Previous studies have correlated loss of protein expression on …

0301 basic medicinePathologymedicine.medical_specialtyHistologyBilIN; PBRM1; biliary dysplasia; cholangiocarcinoma; chromatin remodellingchromatin remodellingKaplan-Meier EstimateBiologymedicine.disease_causeArticleBilIN; PBRM1; biliary dysplasia; cholangiocarcinoma; chromatin remodelingChromatin remodelingchromatin remodelingPathology and Forensic MedicinePBRM1PBRM103 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansBilinIntrahepatic CholangiocarcinomaProportional Hazards ModelsBilINMutationNuclear ProteinsCancerGeneral MedicinePrognosismedicine.diseaseChromatinDNA-Binding Proteinsbiliary dysplasiaCell Transformation Neoplastic030104 developmental biologyBile Duct Neoplasmschemistry030220 oncology & carcinogenesisMutationCarcinogenesischolangiocarcinomaTranscription Factors
researchProduct

Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients

2016

International audience; Tumor-infiltrating T and B lymphocytes could have the potential to affect cancer prognosis. The objective of this study was to investigate the prognostic significance of tumor infiltration by CD8 and CD4 T cells, and B lymphocytes in patients with localized gastric cancer. In a retrospective cohort of 82 patients with localized gastric cancer and treated by surgery we quantitatively assessed by immunohistochemistry on surgical specimen, immune infiltrates of IL-17(+), CD8(+), Foxp3(+), Tbet(+) T cells and CD20(+) B cells both in the tumor core and at the invasive margin via immunohistochemical analyses of surgical specimens. We observed that CD8(+) and IL17(+) T-cell…

0301 basic medicinePathologymedicine.medical_specialtyStromal cellImmune contextureImmunologyB-cellsOvarian-cancer[SDV.CAN]Life Sciences [q-bio]/CancerExpressionFavorable prognosisT-bet[ SDV.CAN ] Life Sciences [q-bio]/Cancerhistology03 medical and health sciencesLong-term survival0302 clinical medicineImmune systemhuman tumorsmedicineImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyLymphocytesB cellOriginal ResearchCD20B cellsbiologybusiness.industrygastric cancerCarcinomaFOXP3medicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisbiology.protein[SDV.IMM]Life Sciences [q-bio]/ImmunologyprognosisbusinessOvarian cancerTertiary lymphoid structuresInfiltration (medical)Lung-cancerCD8
researchProduct

The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency

2017

International audience; A good understanding of the natural history of rare genetic lipid disorders is a pre-requisite for successful patient management. Disease registries have been helpful in this regard. Lipoprotein Lipase Deficiency (LPLD) is a rare, autosomal-recessive lipid disorder characterized by severe hypertriglyceridemia and a very high risk for recurrent acute pancreatitis, however, only limited data are available on its natural course. Alipogene tiparvovec (Glybera (R)) is the first gene therapy to receive Marketing Authorization in the European Union; GENIALL (GENetherapy In the MAnagement of Lipoprotein Lipase Deficiency), a 15-year registry focusing on LPLD was launched in …

0301 basic medicinePediatricsPathologySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]Familial hypercholesterolemiaDisease030204 cardiovascular system & hematologyGeneTHERAPY0302 clinical medicineFamilialRisk FactorsHyperchylomicronemiaAlipogene tiparvovecRegistriesFAMILIAL HYPERCHOLESTEROLEMIAmedia_commonHypertriglyceridemiaPrognosis3. Good healthNatural historySystematic reviewPhenotypeDISEASESSAFETYHyperlipoproteinemia Type ICardiology and Cardiovascular Medicinemedicine.medical_specialtyAPHERESISRegistryFamilial chylomicronemia syndromeGENIALLLysosomal acid lipase deficiencyLipid Metabolism Inborn Errors03 medical and health sciencesLipoprotein lipase deficiencyRare DiseasesGene therapychylomicronemia syndromemedicinemedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseEuropean unionLipoprotein lipase deficiency (LPLD)business.industryALIPOGENE TIPARVOVEC AAV1-LPLS447Xmedicine.diseaseAlipogene tiparvovecLipoprotein Lipase030104 developmental biologyOrphan diseasebusiness
researchProduct

West syndrome: a comprehensive review

2020

AbstractSince its first clinical description (on his son) by William James West (1793–1848) in 1841, and the definition of the classical triad of (1) infantile spasms; (2) hypsarrhythmia, and (3) developmental arrest or regression as “West syndrome”, new and relevant advances have been recorded in this uncommon disorder. New approaches include terminology of clinical spasms (e.g., infantile (IS) vs. epileptic spasms (ES)), variety of clinical and electroencephalographic (EEG) features (e.g., typical ictal phenomena without EEG abnormalities), burden of developmental delay, spectrum of associated genetic abnormalities, pathogenesis, treatment options, and related outcome and prognosis. Aside…

0301 basic medicinePediatricsmedicine.medical_specialtyNeurologyEtiologymedicine.medical_treatmentDermatologyReview Article03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaGeneticmedicineGeneticsHumansInfantile spasmsbusiness.industryInfantWest SyndromeElectroencephalographyGeneral MedicineInfantile SpasmWest syndromemedicine.diseasePrognosisHypsarrhythmiaPsychiatry and Mental healthEpileptic spasms030104 developmental biologyInfantile spasms syndromeEtiologyEpileptic spasmInfantile spasmNeurology (clinical)Neurosurgerymedicine.symptomEpileptic spasmsbusinessSpasms Infantile030217 neurology & neurosurgeryKetogenic diet
researchProduct

Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease.

2015

Background: Intention of the study is to assess the cardiovascular mortality of patients with coronary artery disease (CAD) with the biomarkers of angiogenesis PlGF and its endogenous inhibitor sFlt-1. Methods: The cohort included n = 1848 patients with CAD and 282 subjects without CAD. In 85 patients cardiovascular mortality, as combination of fatal myocardial infarction or any cardiac death, during a median follow-up duration of 3.9 years was reported. Results: In Kaplan–Meier curve analysis PlGF in rising thirds was not predictive regarding outcome (p = 0.54), the same was shown for sFlt-1 (p = 0.44). Cox regression for the fully adjusted model provided a hazard ratio (HR) of 0.8 (p = 0…

0301 basic medicinePlacental growth factorMalemedicine.medical_specialtyClinical BiochemistryCoronary Artery DiseaseKaplan-Meier Estimate030204 cardiovascular system & hematologyPregnancy ProteinsCoronary artery disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoveryNatriuretic Peptide BrainmedicineHumansMyocardial infarctionPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1Proportional hazards modelbusiness.industryBiochemistry (medical)Hazard ratioMiddle Agedmedicine.diseasePrognosisPeptide FragmentsVascular endothelial growth factor030104 developmental biologyEndocrinologychemistryCohortCardiologyFemalebusinessSoluble fms-like tyrosine kinase-1Follow-Up StudiesBiomarkers in medicine
researchProduct

Mitochondrial DNA Replacement Techniques to Prevent Human Mitochondrial Diseases.

2021

Background: Mitochondrial DNA (mtDNA) diseases are a group of maternally inherited genetic disorders caused by a lack of energy production. Currently, mtDNA diseases have a poor prognosis and no known cure. The chance to have unaffected offspring with a genetic link is important for the affected families, and mitochondrial replacement techniques (MRTs) allow them to do so. MRTs consist of transferring the nuclear DNA from an oocyte with pathogenic mtDNA to an enucleated donor oocyte without pathogenic mtDNA. This paper aims to determine the efficacy, associated risks, and main ethical and legal issues related to MRTs. Methods: A bibliographic review was performed on the MEDLINE and Web of S…

0301 basic medicinePoor prognosisLegal positionMitochondrial DNAFarmacologiaWeb of scienceMEDLINEReviewmitochondrial DNABioinformaticsDNA MitochondrialCatalysisMitocondrisInorganic Chemistrylcsh:Chemistry03 medical and health sciencesmitochondrial donation0302 clinical medicineMedicineHumansPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5Spectroscopymitochondrial diseases030219 obstetrics & reproductive medicinebusiness.industryOrganic ChemistryDonor oocyteGeneral MedicineDNAGenetic TherapyComputer Science ApplicationsNuclear DNAMitochondriaClinical trial030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Oocytesmitochondrial replacementthree-parent babybusinessInternational journal of molecular sciences
researchProduct

Predictive validity of the risk SCORE model in a Mediterranean population with dyslipidemia.

2019

Background and aims: Cholesterol treatment for the primary prevention of cardiovascular disease is based on cardiovascular risk, as assessed by the SCORE (Systematic COronary Risk Evaluation) scale. This study aimed to assess the predictive value and clinical utility of the SCORE scale for preventing cardiovascular events and all-cause mortality in people with dyslipidemia and no lipid-lowering treatment. Methods: Patients with dyslipidemia and no lipid-lowering treatment were included from the ESCARVAL-RISK cohort. Cardiovascular risk was calculated by means of the SCORE scale. All deaths and cardiovascular events were recorded for up to five years of follow-up. We calculated sensitivity, …

0301 basic medicinePredictive validityAdultMalemedicine.medical_specialtyTime FactorsPopulationHypercholesterolemia030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicineDiabetes mellitusSCOREmedicineHumansProspective StudiesRegistrieseducationAgededucation.field_of_studyFramingham Risk Scorebusiness.industryReproducibility of ResultsMiddle Agedmedicine.diseaseCardiovascular diseaseCardiovascular riskPrognosis030104 developmental biologyCardiovascular DiseasesSpainCohortDisease ProgressionFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemiaKidney diseaseAtherosclerosis
researchProduct

The expression and prognostic relevance of programmed cell death protein 1 in tongue squamous cell carcinoma

2020

Background Programmed cell death protein 1 (PD‐1) is an immune checkpoint receptor which plays an important role in a patient´s immune responses to microbial and cancer antigens. It is expressed in tumor infiltrating lymphocytes (TILs) with many different malignancies. The aim of the study was to evaluate PD‐1 expression and its prognostic value in tongue cancer. Methods The data of tongue squamous cell carcinoma (TSCC) patients (N=81) treated in Tampere University Hospital between 1999‐2013 was used. Control data consisted of patients with non‐malignant tongue mucous membrane lesions (N=48). The formalin‐fixed paraffin‐embedded samples were stained immunohistochemically and scanned via dig…

0301 basic medicineProgrammed Cell Death 1 Receptorbiomarkkerittongue squamous cell carcinomaLYMPHOCYTES0302 clinical medicineImmunology and AllergyEPIDEMIOLOGYReceptorDISSECTIONAged 80 and over11832 Microbiology and virologyLIGAND 1 PD-L1Mucous membranemolekyylitGeneral MedicineMiddle AgedCANCER3. Good healthTongue Neoplasmsmedicine.anatomical_structure030220 oncology & carcinogenesisimmunohistochemistryCarcinoma Squamous CellSURVIVALImmunohistochemistrysyöpätauditProgrammed cell death protein 1 (PD-1)Microbiology (medical)AdultAdolescentPathology and Forensic Medicine03 medical and health sciencesYoung AdultImmune systemAntigenTonguePOOR-PROGNOSISmedicineBiomarkers TumorHumansNECKAgedmolecular markerbusiness.industryHUMAN-PAPILLOMAVIRUSCancerennusteetprogrammed cell death protein 1 (PD‐1)medicine.diseaseImmune checkpoint030104 developmental biologyCancer researchT-CELLSprognosis3111 Biomedicinebusiness
researchProduct

RNA sequencing for research and diagnostics in clinical oncology.

2020

Molecular diagnostics is becoming one of the major drivers of personalized oncology. With hundreds of different approved anticancer drugs and regimens of their administration, selecting the proper treatment for a patient is at least nontrivial task. This is especially sound for the cases of recurrent and metastatic cancers where the standard lines of therapy failed. Recent trials demonstrated that mutation assays have a strong limitation in personalized selection of therapeutics, consequently, most of the drugs cannot be ranked and only a small percentage of patients can benefit from the screening. Other approaches are, therefore, needed to address a problem of finding proper targeted thera…

0301 basic medicineProteomicsCancer ResearchGenomicsComputational biologyMedical OncologyGenomeTranscriptome03 medical and health sciences0302 clinical medicineNeoplasmsBiomarkers TumorMedicineHumansGeneClinical Oncologybusiness.industrySequence Analysis RNAGene Expression ProfilingRNAComputational BiologyGenomicsMolecular diagnosticsPrognosis030104 developmental biology030220 oncology & carcinogenesisPersonalized medicinebusinessSeminars in cancer biology
researchProduct

Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study.

2019

The objective was to assess quality of life (QoL) in lung cancer survivors, compare it to the general population, and identify factors associated with global QoL, physical functioning, emotional functioning, fatigue, pain, and dyspnea.Data from NSCLC patients who had survived 1 year or longer after diagnosis were collected cross-sectionally in a multicenter study. QoL was assessed with the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and the lung cancer module QLQ-LC13 across different clinical subgroups and compared to age- and sex-standardized general population reference values. Multivariable linear regression analyses wer…

0301 basic medicinePulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyLung NeoplasmsCross-sectional studyPopulation03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineCarcinoma Non-Small-Cell LungSurveys and QuestionnairesMedicineHumansSurvivorsLung cancereducationAgedAged 80 and overeducation.field_of_studybusiness.industryCancerMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyhumanitiesSurvival Rate030104 developmental biologyCross-Sectional StudiesOncologyMulticenter study030220 oncology & carcinogenesisQuality of LifePatient-reported outcomeFemaleActive treatmentbusinessFollow-Up StudiesJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
researchProduct